drugset / Trial / NCT01159236
Molecular Triaging of Newly Diagnosed Breast Cancer
Withdrawn
M.D. Anderson Cancer Center
RandomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if using "gene signatures" can be an effective way to decide the best treatment for breast cancer patients. Gene signatures may be able to help researchers predict who will respond to chemotherapy given before surgery.
Timeline
- Start
- 2010-09
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “Recent developments lead to re-evaluation of study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Epirubicin | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 500 mg/m2 | Intravenous |